| 摘要 |
The invention relates to a mutant cholera holotoxin having reduced toxicity, which functions both as an adjuvant and an antigen carrier. In a particular embodiment, the cholera holotoxin is genetically modified at least at amino acid residue 29 of the A subunit, wherein the genetic modification comprises an amino acid substitution of the wild-type glutamic acid at position 29, wherein the substitution is not an aspartic acid. |
